BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 24
• 26
• 27
• 28
• 29
• 30

• Business

  Omeros Corporation Reports Third Quarter 2017 Financial Results

  For the quarter ended September 30, 2017, total revenues were $21.7 million, all from sales of OMIDRIA.

  November 9, 2017

   · 

  12 min read
• Business

  BioTime Reports Third Quarter Results and Recent Corporate Accomplishments

  Cash, cash equivalents and available for sale securities totaled $18.2 million as of September 30, 2017, compared to $15.8 million as of June 30, 2017.

  November 9, 2017

   · 

  23 min read
• Business

  Synergy Pharmaceuticals Reports Third Quarter 2017 Financial Results and Business Update

  Total net sales were $5.0 million for the third quarter of 2017, a 117.4% increase over the prior quarter.

  November 9, 2017

   · 

  10 min read
• Business

  Aralez Announces Third Quarter 2017 Financial Results And Achieves Profitability on an Adjusted EBITDA Basis for the First Time in the Third Quarter

  Based on the Company’s preliminary 2018 outlook, the Company is expected to transition into a growth phase of its corporate evolution and pivot into a profitable (on an Adjusted EBITDA basis) and growth Company.

  November 9, 2017

   · 

  38 min read
• 

  Business

  Ionis Licenses Novel Antisense Drug for the Treatment of Centronuclear Myopathy to Dynacure

  Ionis earns $5 million license fee from Dynacure.

  November 9, 2017

   · 

  5 min read
• Business

  Galmed Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update

  A conference call and webcast is scheduled for oday at 8:30 a.m. ET / 5:30 a.m. PT.

  November 9, 2017

   · 

  18 min read
• Drug Development

  AcelRx Pharmaceuticals Reports Publication of Manuscript Evaluating Sufentanil Sublingual Tablets for Moderate-to-Severe Acute Pain in the Emergency Department

  This manuscript reports on the results of an open-label, multicenter feasibility study which included opiate-naïve patients who presented to the ED with moderate-to-severe pain due to trauma or injury.

  November 9, 2017

   · 

  5 min read
• Business

  Concert Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Company Update

  Cash, cash equivalents and investments as of September 30, 2017, totaled $207.1 million as compared to $103.4 million as of June 30, 2017.

  November 9, 2017

   · 

  8 min read
• Business

  ReadCoor Collaborates With The Joint Pathology Center

  ReadCoor, a company reinventing omics and pathology with its panomic spatial sequencing platform, today announced a collaboration with The Joint Pathology Center (JPC), the premier pathology reference center for the United States government.

  November 9, 2017

   · 

  2 min read
• Business

  ArQule Reports Third Quarter 2017 Financial Results

  For the quarter ended September 30, 2017, the Company reported a net loss of $6,666,000 or $0.09 per share, compared with a net loss of $5,817,000 or $0.08 per share, for the third quarter of 2016.

  November 9, 2017

   · 

  12 min read